Europe Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Country 2024-2032

Europe Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Country 2024-2032

Report Format: PDF+Excel | Report ID: SR112025A2990

Market Overview:

The Europe hospital acquired disease testing market size reached US$ 3,408.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 12,448.7 Million by 2032, exhibiting a growth rate (CAGR) of 15.02% during 2024-2032.

Report Attribute
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023 US$ 3,408.5 Million
Market Forecast in 2032 US$ 12,448.7 Million
Market Growth Rate (2024-2032) 15.02%


Hospital-acquired diseases (HAD), or nosocomial infections, are illnesses caused by exposure to viral, bacterial and fungal pathogens during hospital visits. Some commonly known infections are catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The various tests used to diagnose these infections are complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, and urinalysis, cultures of the infected area, blood, urine and other body fluids. Other diagnostic tests, such as antimicrobial susceptibility testing (AST), are conducted for the testing of tuberculosis.

The increasing prevalence of hospital-acquired infections across Europe is one of the key factors driving the market. Furthermore, various technological advancements, such as the development of innovative diagnostic instruments and technologies, including flow cytometry, mass spectrometry and near-infrared spectroscopy, are providing a boost to the market growth. Additionally, the growing awareness regarding HADs and the available treatment options among patients, along with extensive research and development (R&D) in the field of medical sciences, are contributing to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the Europe hospital acquired disease testing market report, along with forecasts at the regional and country levels from 2024-2032. Our report has categorized the market based on indication.

Breakup by Indication:

Europe Hospital Acquired Disease Testing Market

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others
     

Breakup by Country:

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Segment Coverage Indication, Country
Countries Covered Germany, France, United Kingdom, Italy, Spain, Others
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the Europe hospital acquired disease testing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Europe hospital acquired disease testing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the Europe hospital acquired disease testing market and who are the key players?
  • What is the degree of competition in the industry?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Europe Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Country 2024-2032
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials